EUCTR2007-002457-24-FIActive, not recruitingNot Applicable
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 1,200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone, or with metformin and not more than one other oral antidiabetic drug (antidiabetic therapy has to be unchanged for 10 weeks prior to informed consent and patients should receive standard diet and exercise counseling)
- •2.Diagnosis of type 2 diabetes prior to informed consent
- •3.Glycosylated haemoglobin A1 (HbA1c) at Visit 1a (Screening):
- •For patients undergoing wash out of previous medication: HbA1c =6.5 to =9.0%
- •For patients not undergoing wash-out of previous medication: HbA1c =7.0 to =10.0%
- •4.Glycosylated haemoglobin A1 (HbA1c) =7.0 to =10.0% at Visit 2 (Start of Run-in)
- •5.Age =18 and = 80 years at Visit 1a (Screening)
- •6.BMI (Body Mass Index) = 40 kg/m2 at Visit 1a (Screening)
- •7.Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1.Myocardial infarction, stroke or TIA within 6 months prior to informed consent
- •2.Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at Visit 1a
- •3.Known hypersensitivity or allergy to the investigational product or its excipients or metformin or placebo
- •4.Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent
- •5.Treatment with an injectable GLP-1 analogue (e.g. exenatide) within 3 months prior to informed consent
- •6.Treatment with insulin within 3 months prior to informed consent
- •7.Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent
- •8.Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse
- •9.Participation in another trial with an investigational drug within 2 months prior to informed consent
- •10.Pre-menopausal women (last menstruation ? 1 year prior to informed consent) who:
- •- are nursing or pregnant,
- •- or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner. No exception will be made.
- •11.Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.
- •12.Renal failure or renal impairment (serum creatinine =1.5 mg/dl as determined at Visit 1a)
- •13.Dehydration by clinical judgement of the investigator
- •14.Unstable or acute congestive heart failure
- •15.Acute or chronic metabolic acidosis (present in patient history)
- •16.Hereditary galactose intolerance
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Clinical trial to confirm the efficacy and safety of tiotropium 5 microgram administered via Respimat device, in patients with cystic fibrosis.Cystic FibrosisEUCTR2010-019802-17-DEBoehringer Ingelheim Pharma GmbH & Co. KG372
Active, not recruiting
Phase 1
A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF).MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary FibrosisEUCTR2019-004167-45-FIBoehringer Ingelheim Finland Ky150
Active, not recruiting
Not Applicable
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite a therapy of metformin in combination with a sulphonylureaEUCTR2007-002450-28-BESCS Boehringer Ingelheim Comm.V800
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic controlEUCTR2007-002448-10-SK450
Active, not recruiting
Phase 1
A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 years of age, with type 2 diabetes and insufficient glycaemic control despite treatment with diet and exercise alonePatients with type 2 diabetes.MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-017004-91-FRBoehringer Ingelheim France83